| First Author | Reijerkerk A | Year | 2004 |
| Journal | J Thromb Haemost | Volume | 2 |
| Issue | 5 | Pages | 769-79 |
| PubMed ID | 15099284 | Mgi Jnum | J:102166 |
| Mgi Id | MGI:3607015 | Doi | 10.1111/j.1538-7836.2004.00682.x |
| Citation | Reijerkerk A, et al. (2004) Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. J Thromb Haemost 2(5):769-79 |
| abstractText | Many studies have indicated that the plasminogen activation system may have a prominent role in cancer. Activation of the zymogen plasminogen into the serine protease plasmin by plasminogen activator is mediated by carboxyterminal basic amino acids in fibrin, including lysines and arginines. Thrombin-activatable fibrinolysis inhibitor (TAFI) is a circulating carboxypeptidase B-type proenzyme that, after activation, removes carboxyterminal lysine or arginine residues in fibrin, resulting in decreased plasminogen activation and attenuated fibrinolysis. To determine directly whether TAFI is involved in primary tumor growth and metastasis formation, we examined the effects of TAFI deficiency on subcutaneous growth and experimentally or spontaneously induced pulmonary metastasis formation of different tumor cell types in mice. In all tumor models TAFI deficiency did not affect the formation and growth of primary and metastasized tumors. |
